Skip to content
Screener

Investing Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$1.61B-241%
Eli Lilly logo
Eli LillyLLY
-$3.92B-16.8%
Pfizer logo
PfizerPFE
$785M-76.0%
Merck & Co. logo
Merck & Co.MRK
-$10.21B-587%
Amgen logo
AmgenAMGN
-$569M-46.3%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$42.74M-2,579%

Other financials

Income statement

See full
Revenue-
Operating income-$445.2M-84.9%
Net income-$453.8M-113%
EPS (diluted)-$2.29-103%

Balance sheet

See full
Cash & equivalents$440.9M+32.2%
Total debt$156.6M+16.6%
Total equity$1.5B-27.8%
Total assets$2.3B-4.7%

Cash flow

See full
Operating cash flow-$354.2M-82.2%
CapEx$1.5M-52.9%
Free cash flow-$355.7M-79.9%

Valuation

See full
Market cap$38.79B+460%
Enterprise value$38.5B+479%

Profitability

See full
Operating margin-88,031.9%-89,488pp
Net margin-76,423.3%-77,733pp
FCF margin-74,273.9%-75,457pp

Returns & leverage

See full
Return on equity-76.7%-923pp
Debt / equity0.1×0.0×
Current ratio6.8×-6.7×

Where this comes from

Reported directly by Revolution Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:10 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-208969
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Purchases of marketable securities(209,733)(510,036)
Maturities of marketable securities383,886497,353
Purchases of property and equipment(1,538)(3,266)
Net cash provided by (used in) investing activities172,615(15,949)
Cash flows from financing activities
Proceeds from issuance of common stock upon at-the-market offering, net of issuance costs226,730
Proceeds from issuance of common stock under equity incentive plans12,209891
Exercise of warrants571

Item 1. Financial Statements.

FAQ

What is Revolution Medicines, Inc.'s investing cash flow?
Revolution Medicines, Inc. (RVMD) reported investing cash flow of $172.62M in Q1 2026.
How has Revolution Medicines, Inc.'s investing cash flow changed year-over-year?
Revolution Medicines, Inc.'s investing cash flow increased by 1182.3% year-over-year, from -$15.95M to $172.62M.
What is the long-term trend for Revolution Medicines, Inc.'s investing cash flow?
Over 3 years (2021 to 2025), Revolution Medicines, Inc.'s investing cash flow has grown at a -7.8% compound annual growth rate (CAGR), from -$150.65M to $118.06M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Revolution Medicines, Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude